Haematopoietic stem cell mobilisation followed by high-dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma

Br J Haematol. 2023 Sep;202(6):1224-1227. doi: 10.1111/bjh.18990. Epub 2023 Jul 24.

Authors

S Asher¹, R Shah¹, S Ings¹, J Horder¹, F Newrick¹, G Nesr¹, R Kesse Adu², M Streetly², S Trompeter¹, L Lee¹, B Wisniowski¹, S Mahmood¹, K Xu¹, X Papanikalaou¹, A McMillan¹, R Popat¹, K Yong¹, J Sive¹, C Kyriakou¹, N Rabin¹

Affiliations

¹ Department of Haematology, University College Hospital London NHS Foundation Trust, London, UK.
² Department of Haematology, Guys and St Thomas' NHS Foundation Trust, London, UK.

PMID: 37488061
DOI: 10.1111/bjh.18990

No abstract available

Publication types

Letter

MeSH terms

Anemia, Sickle Cell* / drug therapy
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation*
Humans
Multiple Myeloma* / drug therapy
Stem Cell Transplantation
Transplantation, Autologous